Recent Updates
Recently added Catalysts
KRYS Positive Sentiment Score: 70/100

Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Key Takeaway: Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. CEO Krish S. Krishnan is scheduled for a fireside chat at 10:40 am ET and will meet with investors throughout the conference. This participation highlights the company's commitment to engaging with the investment community while promoting its innovative genetic medicines aimed at addressing significant medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a major healthcare conference indicates strong visibility for the company.
  • CEO's involvement suggests confidence and commitment to investor relations.
  • Robust pipeline in various fields showcases potential for growth and innovation.

Full Press Release Details

PITTSBURGH, June 05, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:40 am ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 10:40 am ET on Tuesday, June 11, 2024 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Investors and Media:

Frequently Asked Questions

When will Krystal Biotech participate in the healthcare conference?

Krystal Biotech will participate in the Goldman Sachs conference on June 11, 2024.

Who from Krystal Biotech will speak at the conference?

Krish S. Krishnan, Chairman and CEO, will participate in a fireside chat.

What is VYJUVEK®?

VYJUVEK® is Krystal Biotech's first product, a redosable gene therapy.

What areas does Krystal Biotech focus on?

Krystal Biotech focuses on genetic medicines in respiratory, oncology, and dermatology.

Where is Krystal Biotech located?

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.

Last updated: Jun 5, 2024